Faster Drug Launches, Light Protection, Eco-Friendly? How Small Labels Drive Major Market Innovation Upgrades!
The core value of pharmaceutical labels is not to attract consumer attention on crowded shelves. Unlike other label categories that focus heavily on branding and aesthetic design, the pharmaceutical label printing sector places a high priority on functionality, demanding extreme performance, stability, and safety.
Pharmaceutical Label Application Scenarios
Compared to ordinary label materials, pharmaceutical labels must adapt to various highly demanding and stringent technical application scenarios. For example, they need to adhere to small-diameter syringes at low temperatures while also possessing excellent chemical resistance.
Additionally, pharmaceutical labels must be compatible with multiple sterilization processes, including high-pressure steam sterilization, ethylene oxide gas sterilization, gamma ray irradiation, and electron beam irradiation.
Pharmaceutical Label Risk Management
Compared to other industries, the product iteration and launch process in the pharmaceutical industry is extremely lengthy. The average cycle from R&D to market for a new drug is 10 to 15 years, with R&D investments reaching as high as 1.3 billion to 2.8 billion. It is noteworthy that the review process for new drug applications covers not only the safety and efficacy of the drug itself but also the entire drug packaging system. This requires pharmaceutical companies to possess complete test data to confirm that all packaging components, including label materials, will not negatively impact drug quality or medication safety.
Therefore, the demand for risk management in pharmaceutical labels is also very urgent. Drug efficacy and usage safety are the primary principles of the pharmaceutical industry. Companies place extreme importance on risk management issues arising from drug packaging system approvals and material changes, which in turn sets higher standards for the quality control and service capabilities of upstream label suppliers.
Any minor change in label materials could force pharmaceutical companies to restart months-long drug stability tests, significantly increasing their time costs and R&D production expenses. Given the unique qualification verification requirements of the pharmaceutical industry, it is recommended that label printing companies establish comprehensive supporting service systems, strictly control product material changes, proactively extend product change notification periods, and minimize customer validation costs as much as possible.
New Trend in Pharmaceutical Labels: Photosensitive Drug Labels
Currently, the technological upgrade of supporting labels for photosensitive drugs is a key innovation direction in the industry. Light exposure can cause many drugs to undergo photodegradation or other chemical reactions, destroying drug stability and reducing efficacy. This issue is receiving increasing industry attention. The biopharmaceutical market is vast; according to Grand View Research data, the current market size is approximately 400billionto600 billion, and it is expected to exceed $1 trillion by 2030. This will further drive the iteration of light-blocking label technology. At the same time, several new synthetic drugs, such as oral glucagon-like peptide-1 (GLP-1), also have photosensitive properties, creating an urgent need for light-blocking labels.
To meet the rapid growth of the photosensitive drug market, some label material suppliers have accelerated their R&D efforts and launched a series of suitable label products. For example, Avery Dennison has introduced a new UV-blocking label product series. This series of UV-blocking materials effectively prevents ultraviolet rays from damaging drugs, stabilizes drug efficacy, and significantly extends the shelf life of photosensitive medications. Among them, the transparent laminated film product combines UV protection with visual inspection capabilities, meeting the quality verification needs during the production of injectable drugs and providing strong support for pharmaceutical companies’ quality control processes.
Sustainability Progress in Pharmaceutical Labels
Currently, the concept of sustainable development is gradually penetrating the field of pharmaceutical labels. While adhering to the primary principle of ensuring patient medication safety, more and more pharmaceutical companies are actively incorporating sustainable design concepts into new drug launches and existing drug packaging revision projects, promoting the green upgrade of pharmaceutical packaging.
At present, the green transformation of pharmaceutical packaging is mainly concentrated in the secondary packaging sector. The industry is commonly replacing traditional plastic accessories with paper trays and paper inner inserts. Meanwhile, single-use auto-injectors are gradually evolving towards multi-dose reusable versions, effectively reducing the amount of medical waste sent to landfills and lowering the environmental burden of the industry.
In terms of the R&D and implementation of sustainable pharmaceutical label materials, some label material suppliers are creating diversified eco-friendly product matrices tailored to the different green development goals of various pharmaceutical companies. Depending on specific client needs, enterprises can offer multiple environmentally friendly label solutions, such as eco-friendly virgin paper substrates, film liners containing recycled content, and specialized adhesives compatible with HDPE bottle recycling, to meet the green upgrade requirements of mainstream labels for oral solid dosage forms.
Be free to consult us on custom anti-counterfeiting solutions to protect your product and brand, help you increase revenue, and build customer loyalty.
